Innovest Global, Inc. (OTC Markets: IVST) is in the Conglomerates industry, a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. Our primary growth strategy is to acquire niche, high-growth businesses that are capable of generating significant annual revenue. Planned subsidiaries operate across telehealth, biotech, building materials, commercial energy, business-to-business distribution, national call center and auto sales.
IVST is up 2000% YTD from $0.023 on zero revenue to 0.50 on $34 million revenue.
IVST added $34 million sales run rate YTD through growth model of acquisitions.
IVST revenues are up 6800% on the year via acquisitions and increased sales. Pending Acquisition will add $12 Million in revenue.
Only 11.8M shares in the Float unchanged for over two years. No convertible debts, warrants, or options.
IVST has closed the acquisition of Authority National Supply (ANS) is closed. ANS was our sixth transaction to date, and has generated $22.8 million in sales through the first three quarters of 2018. IVST now has approximately 55 employees and $34 million in annual run-rate revenue.
Innovest Global Signed an LOI to Acquire Midwest Curtainwalls, a $12 Million Revenue and Profitable Business. Midwest is a company that will add to our Construction and Building Materials efforts. They generate $10-$12 million in annual revenue from specialty commercial construction contracts, with projections of $2.4 million in profit from current contract. Based out of Cleveland, Ohio, IVST is easily one of the better fundamental companies trading on the OTC marketplace. Innovest Global, Inc. is already up 10-fold in 2018. Based upon the company’s strong fundamental AND technical picture, Innovest Global, Inc. could easily hit an all-time high by the end of 2018.
IVST owns 20% of StemVax Therapeutics which is the first company in its Biotech Division. StemVax Therapeutics is a Translational Biotechnology Company that develops novel therapies for brain tumor patients. We focus our efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma Multiforme (GBM), a devastating brain cancer. We also focus our research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells. Lead by world-renowned neuroscientist, Dr. Dwain Morris-Irvin, the Biotech & Health Sciences Division is currently focused on commercializing StemVax’s cancer vaccination therapy technology. The cancer vaccination therapy technology was just recently awarded a U.S. patent! We seek to make a difference in patient’s lives bringing new beginnings to the market by developing novel therapeutics. IVST’s management team has been extremely busy with its pending mega-acquisition of a building materials company, which produces $34 million in annual revenues. IVST has the vision and model of Berkshire-Hathaway, we look forward to its evolution!